REG - Indivior PLC - Indivior to Commence Trading on Nasdaq

IndiviorAnnouncement

12/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230612:nRSL3025Ca&default-theme=true

RNS Number : 3025C  Indivior PLC  12 June 2023

 

 

 

 

For Immediate Release

 

Indivior to Commence Trading on Nasdaq

Company to Ring Opening Bell June 14 to Bring Awareness to Addiction
Treatment;

Company Will Maintain Premium Listing on London Stock Exchange

 

Richmond, VA, June 12, 2023 - Indivior PLC (LSE: INDV), a global
pharmaceutical company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD) and serious mental illnesses,
today announces that the U.S. Securities & Exchange Commission (SEC)
declared its registration statement on Form 20-F effective on June 9. Trading
in Indivior ordinary shares on the Nasdaq Global Select Market will commence
at U.S. market open today.

 

Indivior will retain its premium listing on the London Stock Exchange and
inclusion in the FTSE 250 index, and its ordinary shares will trade on both
exchanges under the ticker symbol "INDV." The Company also notes that no
shares are being offered as part of the additional U.S. listing.

 

"The additional U.S. listing of Indivior shares is an important milestone,"
said Mark Crossley, CEO. "We believe it will bring additional exposure to both
Indivior and the disease space in the U.S., which is our largest opportunity
market. Over time, we expect it will facilitate increased ownership by
additional  U.S.-based biopharma investors. We also are mindful of the
significant unmet need for opioid use disorder treatment in the U.S., and are
hopeful our U.S. listing will help raise awareness of the opioid epidemic."

 

Crossley, along with a number of patients and their families, will ring the
Opening Bell at the Nasdaq MarketSite in Times Square on June 14 to celebrate
the company's Nasdaq listing and raise awareness of the millions of people
affected by substance use disorders and mental health challenges. Members of
the Indivior executive team and employees also will be in attendance.

 

"When we ring the Nasdaq opening bell, we hope to bring focus to our patients
and the immense challenges they face," said Crossley. "Addiction is often
misunderstood as a personal moral failing, but the reality is that it is a
disease that requires medical treatment like any other chronic illness. At
Indivior, we want to change how substance use disorders, mental illness, and
opioid overdose are viewed and treated. We are committed to ending the stigma
of addiction and helping our patients on their journey to recovery."

 

Indivior launched a new patient-focused campaign (http://www.indivior.com/) to
complement the company's Nasdaq listing and the bell ringing event. The
patients in attendance at the bell ringing are featured in the ad campaign,
which humanizes addiction and shows that recovery is possible.

 

The patient-focused campaign is running across digital platforms, print,
newsletters and outside advertising in Times Square. To learn more, visit
indivior.com/en/investors (http://indivior.com/en/investors) .

 

Important Cautionary Note Regarding Forward-Looking Statements

This announcement contains certain statements that are
forward-looking. Forward-looking statements include, among other things,
statements regarding the timing of our planned additional U.S. stock
exchange listing, expectations regarding future index inclusion, and other
statements containing the words "believe," "anticipate," "plan," "expect,"
"intend," "estimate," "forecast," "strategy," "target," "guidance," "outlook,"
"potential," "project," "priority," "may," "will," "should," "would," "could,"
"can," "outlook," "guidance," the negatives thereof, and variations thereon
and similar expressions. By their nature, forward-looking statements involve
risks and uncertainties as they relate to events or circumstances that may or
may not occur in the future.

 

Actual results may differ materially from those expressed or implied in such
statements because they relate to future events. Various factors may cause
differences between Indivior's expectations and actual results, including,
among others, the material risks described in the most recent Indivior PLC
Annual Report and in subsequent releases; our ability to commercialize and
market acceptance of new products; the substantial litigation and ongoing
investigations to which we are or may become a party; our reliance on third
parties to manufacture commercial supplies of most of our products, conduct
our clinical trials and at times to collaborate on products in our pipeline;
our ability to comply with legal and regulatory settlements, healthcare laws
and regulations, requirements imposed by regulatory agencies and payment and
reporting obligations under government pricing programs; risks related to the
manufacture and distribution of our products, some of which are controlled
substances; market acceptance of our products as well as our ability to
commercialize our products and compete with other market participants; the
uncertainties related to the development of new products, including through
acquisitions, and the related regulatory approval process; our dependence on a
small number of significant customers; our ability to retain key personnel or
attract new personnel; our dependence on third-party payors for the
reimbursement of our products and the increasing focus on pricing and
competition in our industry; unintended side effects caused by the clinical
study or commercial use of our products; our use of hazardous materials in our
manufacturing facilities; our import, manufacturing and distribution of
controlled substances; our ability to successfully execute acquisitions,
partnerships, joint ventures, dispositions or other strategic acquisitions;
our ability to protect our intellectual property rights and the substantial
cost of litigation or other proceedings related to intellectual property
rights; the risks related to product liability claims or product recalls; the
significant amount of laws and regulations that we are subject to, including
due to the international nature of our business; macroeconomic trends and
other global developments such as the COVID-19 pandemic; the terms of our debt
instruments, changes in our credit ratings and our ability to service our
indebtedness and other obligations as they come due; changes in applicable tax
rate or tax rules, regulations or interpretations; and our ability to realize
our deferred tax assets.

 

Forward-looking statements speak only as of the date that they are made and
should be regarded solely as our current plans, estimates and beliefs. Except
as required by law, we do not undertake and specifically decline any
obligation to update, republish or revise forward-looking statements to
reflect future events or circumstances or to reflect the occurrences of
unanticipated events.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of substance use disorder (SUD). Indivior is dedicated
to transforming SUD from a global human crisis to a recognized and treated
chronic disease. Building on its global portfolio of OUD treatments, Indivior
has a pipeline of product candidates designed to both expand on its heritage
in this category and potentially address other chronic conditions and
co-occurring disorders of SUD, including alcohol use disorder and cannabis use
disorder. Headquartered in the United States in Richmond, VA, Indivior
employs more than 1,000 individuals globally and its portfolio of products is
available in 39 countries worldwide. Visit www.indivior.com to learn more.
Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.

 

Media Contacts:

 

US Media:

Ben Atkins

Vice President, Communications

Indivior PLC

Tel: 424-844-3244

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts:

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLMATMTBMBPJ